Meet
Caroline Le

She/Her
Senior Associate

Caroline Le supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.

She utilizes her content expertise in health policy and health equity to assist clients as they strategize policy decisions.

Prior to joining Avalere, Caroline served as a policy intern at the North Carolina Department of Health and Human Services. Caroline analyzed trends in COVID-19 case rates and hospitalizations and established guidance to urge North Carolinian K–12 schools to adopt preventative protocols against viral spread. Additionally, she has held health policy roles at Families USA, the National Partnership for Women and Families, Community Catalyst, and the US House of Representatives.

Caroline holds a BSPH in health policy and management from the University of North Carolina at Chapel Hill.

Authored Content

January 13, 2025 | Insights & Analysis > Drug Pricing and Affordability

Three Takeaways from the CMS MFP Justifications for IPAY 2026
CMS released the rationale for the maximum fair prices under the Medicare Drug Price Negotiation Program for Year 1 drugs.
December 4, 2024 | Insights & Analysis > Drug Pricing and Affordability

IRA Negotiation Impact on Part B Beneficiary OOP Costs
Avalere finds that between 0.03% and 0.1% of Medicare FFS beneficiaries would experience lower OOP costs for the first 10 Part B drugs likely to be negotiated.
October 17, 2024 | Insights & Analysis > Drug Pricing and Affordability

Stakeholders Can Engage USP During DC 2025 Comment Period
The USP DC 2025 Draft is open for public comment until October 31, allowing stakeholders to engage with the USP even in years without an update to the MMG.
October 3, 2024 | Insights & Analysis > Federal and State Policy

VP Debate Highlights Healthcare Policy Differences
During the debate, VP candidates outlined their views on healthcare topics such as the ACA, drug pricing, manufacturing, reproductive rights, and mental health.
September 16, 2024 | Insights & Analysis > Federal and State Policy

IRA Inflation Rebate Impact on Part B Beneficiary OOP Costs
Avalere finds that between 0.1% and 0.2% of Medicare FFS beneficiaries would experience lower OOP costs for the Part B drugs subject to Q3 2024 inflation rebates.
September 11, 2023 | Insights & Analysis > Coverage and Payment > Federal and State Policy

Physician Payment for Some Services Lags Behind Inflation
Physician reimbursement for some services under Medicare FFS has declined, while payment increased for the same services in the hospital outpatient setting.

March 23, 2023 | Insights & Analysis > Federal and State Policy

Biden’s 2024 Budget: New Drug Pricing and Coverage Policies
The Biden administration’s budget outlines a healthcare policy agenda focused on drug pricing, coverage reform, infectious diseases, and biomedical research.